OncoMatch/Clinical Trials/NCT06251310
SW-682 in Advanced Solid Tumors
Is NCT06251310 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including SW-682 and Combination Therapy for advanced solid tumor.
Treatment: SW-682 · Combination Therapy — This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Mesothelioma
Biomarker criteria
Allowed: NF2 mutation
Mesothelioma with or without NF2 mutations; Advanced solid tumors with NF2 mutations
Allowed: FAT1 mutation
Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE)
Allowed: LATS1 mutation
Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE)
Allowed: LATS2 mutation
Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE)
Allowed: YAP1 fusion
YAP fusions
Allowed: WWTR1 WWTR1-CAMTA1 fusion
WWTR1-CAMTA1 in EHE
Disease stage
Required: Stage IV
Metastatic disease required
Histologically confirmed, metastatic, or unresectable solid cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate hepatic function
Cardiac function
no clinically significant cardiac disease or abnormal cardiac parameters
Adequate bone marrow, kidney, hepatic, and coagulation function; Clinically significant cardiac disease or abnormal cardiac parameters [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SpringWorks Clinical Trial Site · Scottsdale, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- SpringWorks Clinical Trial Site · Los Angeles, California
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify